PubRank
Search
About
Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma
Clinical Trial ID NCT02077114
PubWeight™ 9.03
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT02077114
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Trial Watch: Peptide-based anticancer vaccines.
Oncoimmunology
2015
1.13
2
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
Clin Cancer Res
2015
1.09
3
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.
Oncoimmunology
2015
1.06
4
Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.
Front Immunol
2015
1.04
5
Trial watch: IDO inhibitors in cancer therapy.
Oncoimmunology
2014
1.01
6
Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells.
Front Oncol
2014
0.85
7
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.
Ther Adv Med Oncol
2016
0.81
8
Indoleamine 2,3-dioxygenase vaccination.
Oncoimmunology
2015
0.78
9
The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.
Oncotarget
2016
0.76
10
The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies.
Trends Immunol
2016
0.75
Next 100